University of Minnesota
This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes among 128 adults with alcohol use disorder (AUD) and obesity.
This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes (alcohol intake, cravings, self-control, affect, quality of life, physiologic data; collected using validated questionnaires and in one's natural environments using ecological momentary assessment (EMA) and wearable devices \[i.e., activity/health trackers\]) among 128 adults (18 to 65 years old) with alcohol use disorder (AUD) and obesity (body mass index (BMI) \>/= 30). We also seek to develop personal causal models for…
Inclusion Criteria: * Age 18-65 years * Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for mild or moderate AUD * \>/=1 bout of heavy drinking (defined as \>/= 4 drinks/day for females; \>/= 5 drinks/day for males) within the last month * Have an interest in reducing or quitting alcohol intake * Have obesity (defined as BMI \>/= 30 kg/m2) at screening * Ability to provide informed consent before any trial-related activities Exclusion Criteria: * Impaired ability to provide consent to a clinical trial and/or comply with study procedures and/or measures using a sm…
Participants in this arm will receive 42 weeks of treatment with semaglutide
Participants in this arm will receive 42 weeks of placebo
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.